Display options
Cite
Cocci A, Di Maida F, Russo GI, et al. How Atypical Penile Curvature Influence Clinical Outcomes in Patients with Peyronie's Disease Receiving Collagenase . World J Mens Health. 2019;38(1):78-84doi: 10.5534/wjmh.190026.
Cocci, A., Di Maida, F., Russo, G. I., Di Mauro, M., Cito, G., Falcone, M., Minervini, A., Cacciamani, G., Campi, R., Mari, A., Sessa, F., & Mondaini, N. (2020). How Atypical Penile Curvature Influence Clinical Outcomes in Patients with Peyronie's Disease Receiving Collagenase . The world journal of men's health, 38(1), 78-84. https://doi.org/10.5534/wjmh.190026
Cocci, Andrea, et al. "How Atypical Penile Curvature Influence Clinical Outcomes in Patients with Peyronie's Disease Receiving Collagenase ." The world journal of men's health vol. 38,1 (2020): 78-84. doi: https://doi.org/10.5534/wjmh.190026
Cocci A, Di Maida F, Russo GI, Di Mauro M, Cito G, Falcone M, Minervini A, Cacciamani G, Campi R, Mari A, Sessa F, Mondaini N. How Atypical Penile Curvature Influence Clinical Outcomes in Patients with Peyronie's Disease Receiving Collagenase . World J Mens Health. 2020 Jan;38(1):78-84. doi: 10.5534/wjmh.190026. Epub 2019 May 29. PMID: 31190485; PMCID: PMC6920074.
Copy Download .nbib Format: NLM
Share it on

World J Mens Health. 2020 Jan;38(1):78-84. doi: 10.5534/wjmh.190026. Epub 2019 May 29.

How Atypical Penile Curvature Influence Clinical Outcomes in Patients with Peyronie's Disease Receiving Collagenase .

The world journal of men's health

Andrea Cocci, Fabrizio Di Maida, Giorgio Ivan Russo, Marina Di Mauro, Gianmartin Cito, Marco Falcone, Andrea Minervini, Giovanni Cacciamani, Riccardo Campi, Andrea Mari, Francesco Sessa, Nicola Mondaini

Affiliations

  1. Department of Urology, Careggi Hospital, University of Florence, Florence, Italy. [email protected].
  2. Department of Urology, Careggi Hospital, University of Florence, Florence, Italy.
  3. Department of Urology, Vittorio Emanuele II, University of Catania, Catania, Italy.
  4. Department of Urology, University of Turin, Turin, Italy.
  5. Department of Urology, University of Verona, Verona, Italy.
  6. Urology Section, Villa Donatello Clinic, Sesto Fiorentino, Italy.

PMID: 31190485 PMCID: PMC6920074 DOI: 10.5534/wjmh.190026

Abstract

PURPOSE: The aim of this study was to evaluate the efficacy of collagenase Clostridium histolyticum (CCH) in patients with Peyronie's disease (PD) suffering from atypical deformities.

MATERIALS AND METHODS: We retrospectively collected data of patients with atypical penile curvature (PC) secondary to PD. All patients underwent a modified treatment protocol, consisting of 3 intralesional injections of 0.9 mg of CCH performed at 4-week intervals at the point of maximum PC. Patients were instructed to follow a strict routine, involving daily modeling of erect penis and stretching at the urinary toilette time, two minutes each. Success was defined as a decrease in PC of ≥20° from baseline.

RESULTS: Sixty-five patients were included in the analysis. Median age was 59.0 years (interquartile range [IQR], 53.0 to 63.0 years), median curvature 40.0° (IQR, 30.0° to 45.0°) median duration of the disease 12.0 years (IQR, 6.5 to 24.0 years). Fifty-three patients (81.54%) had ventral PC, 7 (10.77%) hourglass PC, and 5 (7.69%) shortening PC. Median changes of PC were -20.0 (IQR, -20.0 to -10.0; p<0.01) in ventral PC, -20.0 (IQR, -20.0 to 0; p<0.01) in hourglass and -15.0 (IQR, -15.0 to -15.0; p<0.01) in shortening PC. At Kruscal-Wallis test, significant differences between groups were not found. The rate of PC success was 56.60% (30/53) in ventral PC, 57.14% (4/7) in hourglass and 20.00% (1/5) in shortening PC (p=0.29). Treatment success was not influenced by characteristics of curvature (odds ratio=0.66; p=0.20).

CONCLUSIONS: CCH intralesional injections could represent an effective therapeutic option for the conservative management of patients with atypical PC.

Copyright © 2020 Korean Society for Sexual Medicine and Andrology.

Keywords: Collagenases; Intralesional injections; Penile induration; Peyronie's disease; Therapeutics

Conflict of interest statement

The authors have nothing to disclose.

References

  1. J Sex Med. 2011 Dec;8(12):3446-51 - PubMed
  2. J Sex Med. 2018 Oct;15(10):1472-1477 - PubMed
  3. BJU Int. 2010 Oct;106(8):1178-80 - PubMed
  4. Sex Med Rev. 2019 Apr;7(2):338-348 - PubMed
  5. J Urol. 1993 Jan;149(1):56-8 - PubMed
  6. J Urol. 2013 Jul;190(1):199-207 - PubMed
  7. Biochemistry. 1987 Feb 10;26(3):681-7 - PubMed
  8. J Sex Med. 2018 May;15(5):716-721 - PubMed
  9. J Sex Med. 2015 Apr;12(4):1072-9 - PubMed
  10. Urology. 2017 Jun;104:102-109 - PubMed
  11. J Sex Med. 2017 Nov;14(11):1430-1437 - PubMed
  12. J Sex Med. 2016 Jun;13(6):905-23 - PubMed
  13. J Urol. 1985 Aug;134(2):280-3 - PubMed
  14. J Sex Med. 2015 Dec;12(12):2492-8 - PubMed
  15. J Urol. 2015 Dec;194(6):1704-7 - PubMed
  16. J Sex Med. 2015 Jan;12(1):248-58 - PubMed
  17. BJU Int. 2018 Oct;122(4):680-687 - PubMed
  18. Sex Med Rev. 2017 Apr;5(2):211-221 - PubMed
  19. BJU Int. 2017 Nov;120(5):717-723 - PubMed
  20. Urol Res. 1982;10(3):135-40 - PubMed
  21. J Urol. 2015 Sep;194(3):745-53 - PubMed
  22. J Sex Med. 2008 Aug;5(8):1977-84 - PubMed
  23. J Sex Med. 2013 Mar;10(3):653-60 - PubMed
  24. J Sex Med. 2008 Jan;5(1):180-7 - PubMed
  25. Urology. 1997 Jun;49(6):822-30 - PubMed
  26. Andrology. 2018 Jul;6(4):564-567 - PubMed
  27. J Sex Med. 2007 Nov;4(6):1527-38 - PubMed

Publication Types